Cargando…
Reactivation of SARS-CoV-2 infection following recovery from COVID-19
INTRODUCTION: Many individuals test positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA after recovering from the coronavirus disease (COVID-19), but the incidence of reactivation is unknown. We, therefore, estimated the incidence of reactivation among individuals who had r...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7869688/ https://www.ncbi.nlm.nih.gov/pubmed/33848891 http://dx.doi.org/10.1016/j.jiph.2021.02.002 |
_version_ | 1783648676775723008 |
---|---|
author | Chen, Zhihai Xie, Wen Ge, Ziruo Wang, Yajie Zhao, Hong Wang, Jingjing Xu, Yanli Zhang, Wei Song, Meihua Cui, Shuping Wang, Xiankun Pan, Calvin Q. |
author_facet | Chen, Zhihai Xie, Wen Ge, Ziruo Wang, Yajie Zhao, Hong Wang, Jingjing Xu, Yanli Zhang, Wei Song, Meihua Cui, Shuping Wang, Xiankun Pan, Calvin Q. |
author_sort | Chen, Zhihai |
collection | PubMed |
description | INTRODUCTION: Many individuals test positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA after recovering from the coronavirus disease (COVID-19), but the incidence of reactivation is unknown. We, therefore, estimated the incidence of reactivation among individuals who had recovered from COVID-19 and determined its predictors. METHODS: In this retrospective cohort study, patients with COVID-19 were followed up for at least 14 days after two consecutive negative SARS-CoV-2 polymerase chain reaction test results obtained ≥24 h apart, and the frequency of SARS-CoV-2 reactivation was assessed. RESULTS: Of the 109 patients, 29 (27%) experienced reactivation, and seven (24%) of these were symptomatic. The mean period for the real-time PCR tests for SARS-CoV-2 from negative to positive results was 17 days. Compared with patients without reactivation, those with reactivation were significantly younger and more likely to have a lymphocyte count of <1500/μL (odds ratio [OR]: 0.34, 95% confidence interval [CI]: 0.12–0.94) and two or fewer symptoms (OR: 0.20, 95% CI: 0.07–0.55) during the initial episode. CONCLUSION: Risk-stratified surveillance should be conducted among patients who have recovered from COVID-19. |
format | Online Article Text |
id | pubmed-7869688 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78696882021-02-09 Reactivation of SARS-CoV-2 infection following recovery from COVID-19 Chen, Zhihai Xie, Wen Ge, Ziruo Wang, Yajie Zhao, Hong Wang, Jingjing Xu, Yanli Zhang, Wei Song, Meihua Cui, Shuping Wang, Xiankun Pan, Calvin Q. J Infect Public Health Article INTRODUCTION: Many individuals test positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA after recovering from the coronavirus disease (COVID-19), but the incidence of reactivation is unknown. We, therefore, estimated the incidence of reactivation among individuals who had recovered from COVID-19 and determined its predictors. METHODS: In this retrospective cohort study, patients with COVID-19 were followed up for at least 14 days after two consecutive negative SARS-CoV-2 polymerase chain reaction test results obtained ≥24 h apart, and the frequency of SARS-CoV-2 reactivation was assessed. RESULTS: Of the 109 patients, 29 (27%) experienced reactivation, and seven (24%) of these were symptomatic. The mean period for the real-time PCR tests for SARS-CoV-2 from negative to positive results was 17 days. Compared with patients without reactivation, those with reactivation were significantly younger and more likely to have a lymphocyte count of <1500/μL (odds ratio [OR]: 0.34, 95% confidence interval [CI]: 0.12–0.94) and two or fewer symptoms (OR: 0.20, 95% CI: 0.07–0.55) during the initial episode. CONCLUSION: Risk-stratified surveillance should be conducted among patients who have recovered from COVID-19. The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. 2021-05 2021-02-08 /pmc/articles/PMC7869688/ /pubmed/33848891 http://dx.doi.org/10.1016/j.jiph.2021.02.002 Text en © 2021 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Chen, Zhihai Xie, Wen Ge, Ziruo Wang, Yajie Zhao, Hong Wang, Jingjing Xu, Yanli Zhang, Wei Song, Meihua Cui, Shuping Wang, Xiankun Pan, Calvin Q. Reactivation of SARS-CoV-2 infection following recovery from COVID-19 |
title | Reactivation of SARS-CoV-2 infection following recovery from COVID-19 |
title_full | Reactivation of SARS-CoV-2 infection following recovery from COVID-19 |
title_fullStr | Reactivation of SARS-CoV-2 infection following recovery from COVID-19 |
title_full_unstemmed | Reactivation of SARS-CoV-2 infection following recovery from COVID-19 |
title_short | Reactivation of SARS-CoV-2 infection following recovery from COVID-19 |
title_sort | reactivation of sars-cov-2 infection following recovery from covid-19 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7869688/ https://www.ncbi.nlm.nih.gov/pubmed/33848891 http://dx.doi.org/10.1016/j.jiph.2021.02.002 |
work_keys_str_mv | AT chenzhihai reactivationofsarscov2infectionfollowingrecoveryfromcovid19 AT xiewen reactivationofsarscov2infectionfollowingrecoveryfromcovid19 AT geziruo reactivationofsarscov2infectionfollowingrecoveryfromcovid19 AT wangyajie reactivationofsarscov2infectionfollowingrecoveryfromcovid19 AT zhaohong reactivationofsarscov2infectionfollowingrecoveryfromcovid19 AT wangjingjing reactivationofsarscov2infectionfollowingrecoveryfromcovid19 AT xuyanli reactivationofsarscov2infectionfollowingrecoveryfromcovid19 AT zhangwei reactivationofsarscov2infectionfollowingrecoveryfromcovid19 AT songmeihua reactivationofsarscov2infectionfollowingrecoveryfromcovid19 AT cuishuping reactivationofsarscov2infectionfollowingrecoveryfromcovid19 AT wangxiankun reactivationofsarscov2infectionfollowingrecoveryfromcovid19 AT pancalvinq reactivationofsarscov2infectionfollowingrecoveryfromcovid19 |